Source link : https://www.newshealth.biz/health-news/novel-therapy-linked-to-cognitive-benefit-in-schizophrenia/
TOPLINE: Xanomeline/trospium chloride, a novel M1/M4 muscarinic receptor agonist, is linked to significant cognitive improvement in patients with acute schizophrenia and cognitive impairment in pooled data from two phase 3 trials. METHODOLOGY: Combined data from two 5-week inpatient phase 3 trials were used to evaluate the efficacy of xanomeline/trospium monotherapy vs placebo in 357 adult […]
Author : News Health
Publish date : 2025-01-17 10:40:39
Copyright for syndicated content belongs to the linked Source.